TITLE

How the FDA May Kill Millions In the U.S

AUTHOR(S)
Forbes, Steve
PUB. DATE
February 2011
SOURCE
Forbes Asia;Feb2011, Vol. 7 Issue 2, p11
SOURCE TYPE
Periodical
DOC. TYPE
Article
ABSTRACT
The article discusses issues related to growing bureaucratic approach in the U.S. Food & Drug Administration (FDA). It has been stated that the play-it-safe attitude of the FDA due to interference of the U.S. Congress is creating a devastating and potentially deadly impact on human lives. It has been stated that failure of government regulation has prevented the pharmaceutical industry to develop a reliable new class of antibiotics.
ACCESSION #
58698841

 

Related Articles

  • FDA's Vancocin Rule-Bend: Generic Floodgate's Future? Osborne, Randy // BioWorld Insight;7/27/2009, Vol. 17 Issue 30, p1 

    The article offers information on the move of ViroPharma to prove that its manufactured drug, vancocin is not highly soluble. It mentions that the medicine is approved by the U.S. Food & Drug Administration (FDA) for the treatment of antibiotic-associated pseudomembranous colitis. It relates...

  • Companies may limit use to vets only. JALONICK, MARRY CLARE // Farm & Dairy;4/3/2014, Vol. 100 Issue 28, pA14 

    The article presents views of the U.S. Food and Drug Administration (FDA) on the decision of pharmaceutical companies to withdraw the use of antibiotics in animals that are used for meat.

  • PR View. Moravick, Ann // Medical Marketing & Media;Apr2008, Vol. 43 Issue 4, p32 

    The author reflects on the importance of active leadership in pharmaceutical industry (PI). She asserts the need of the PI to search the comments of their products on the Web site, instead of waiting the intervention of the U.S. Congress. A reflection on the other strategies to be considered by...

  • Senate Backs Pediatric Drug Testing.  // Pharmaceutical Executive;Sep2003, Vol. 23 Issue 9, p22 

    Reports on the approval of a legislation by the U.S. Senate that authorize the U.S. Food and Drug Administration to require pharmaceutical firms to test new drugs in children. Conduction of a pediatric safety and efficacy tests on new drugs generally prescribed for children.

  • Bills Target Post-Approval Period.  // Pharmaceutical Executive;Jul2005, Vol. 25 Issue 7, p26 

    Reports on the demand of members of the U.S. Congress and health professionals for the U.S. Food and Drug Administration to do more to ensure drug safety. Placement of drug risk information on its Internet site; Establishment of an in-house board to weigh drug safety concerns; Requirement of...

  • US regulators and the country's top cancer doctors urged Congress to help end the shortages of more than a hundred drugs, including those for deadly tumors.  // MondayMorning;6/11/2012, Vol. 20 Issue 23, p1 

    The article informs that the U.S. House and Senate are working to merge recent bills that would require drugmakers to notify the Food and Drug Administration (FDA) when they expect halt in production of medicines. According to the FDA, generic drugmakers are struggling with limited manufacturing...

  • Tracking Washington.  // MondayMorning;11/21/2011, Vol. 19 Issue 42, p6 

    The article discusses the proposals in the U.S. Congress that would allow drug manufacturers to bypass customary clinical trial requirements before the products are brought to market. The proposals will factor in Congressional talks to reauthorize the fee system used by pharmaceutical companies...

  • FDAAA Boosts Fees, Broadens Disclosure. Wechsler, Jill // BioPharm International;Nov2007, Vol. 20 Issue 11, p14 

    The article focuses on the Food and Drug Administration Amendment Act (FDAAA) that was enacted by the U.S. Congress. It relates that the enactment of the FDAA has allowed for the continuation of the Prescription Drug User Fee program. Moreover, an overview is provided on the changes that was...

  • The balancing act.  // Nature Reviews Drug Discovery;Sep2003, Vol. 2 Issue 9, p683 

    Regulatory changes in the United States signal good times ahead for the producers of generic drugs. Meanwhile, more facts are needed to ensure that the incentives for innovation remain.

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics